3 transcripts
SDGR
Earnings call transcript
NASDAQ
2024 Q2
31 Jul 24
with the preclinical package for this IND-ready program. Given SOS1 inhibition is expected to be used in combination with KRAS and other MAPK pathway inhibitors, we
SDGR
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
completing the SOS1 development candidate package and BMS have been conducting IND enabling studies. The transfer of information from BMS
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
pharmacokinetics, pharmacodynamics and preliminary anti-tumor data activity package for SGR-1505, our MALT1 inhibitor. In addition to adding clinical sites
- Prev
- 1
- Next